Improving COVID-19 Vaccine Coverage in Patients With Autoimmune and Inflammatory Diseases.

Tiphaine GoulenokChrystelle FrancoisCéline MendesFatima FarhiJean-Francois AlexandraDiane RouzaudThomas PapoKarim Sacre

Published in: The Journal of rheumatology (2021)

In December 2020, France began vaccinations using the messenger RNA (mRNA) vaccine for coronavirus disease 2019 (COVID-19) to combat the SARS-CoV-2 pandemic. Based on the risk for severe COVID-19, patients with autoimmune diseases (AIDs) who are receiving, or about to receive, steroids or immunosuppressive drugs have been prioritized for vaccination.1.

Keyphrases

coronavirus disease
sars cov
respiratory syndrome coronavirus
drug induced
early onset
healthcare
antiretroviral therapy